Canagliflozin in Children with Type 2 Diabetes

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

5 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%). Study drug or placebo would be taken alone or with metformin or insulin as needed. Monitoring tests include blood, urine, physical exams, vital signs, blood sugar and ketone monitoring, diabetes management counseling.

Eligibility & Criteria

IRB #:
19-016066
Official Title:
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to<18 years) with Type 2 Diabetes Mellitus
Study Phase:
Phase III
Eligible Age Range:
10 - 17 Years
Gender:
All
Study Categories: